| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-05-15 |
| タイトル |
|
|
タイトル |
Highly bioavailable curcumin derivative ameliorates Crohn’s disease symptoms: A randomized, double-blind, multicenter study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
bioavailability |
| キーワード |
|
|
主題 |
cytokine inhibition |
| キーワード |
|
|
主題 |
inflammatory bowel disease |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| その他のタイトル |
|
|
その他のタイトル |
A new curcumin derivative for Crohn’s disease |
| 著者 |
Sugimoto, Ken
Ikeya, Kentaro
Bamba, Shigeki
Andoh, Akira
Yamasaki, Hiroshi
Mitsuyama, Keiichi
Nasuno, Masanao
Tanaka, Hiroki
Matsuura, Ai
Kato, Masaichi
Ishida, Natsuki
Tamura, Satoshi
Takano, Ryosuke
Tani, Shinya
Osawa, Satoshi
Nishihira, Jun
Hanai, Hiroyuki
|
| 書誌情報 |
Journal of Crohn's and Colitis
巻 14,
号 12,
p. 1693-1701,
発行日 2020-12
|
| 出版者 |
|
|
出版者 |
Oxford University Press |
| 権利 |
|
|
権利情報 |
This is a pre-copyedited, author-produced version of an article accepted for publication in "Journal of Crohn's and Colitis"" following peer review. The version of record "Ken Sugimoto, Kentaro Ikeya, Shigeki Bamba, Akira Andoh, Hiroshi Yamasaki, Keiichi Mitsuyama, Masanao Nasuno, Hiroki Tanaka, Ai Matsuura, Masaichi Kato, Natsuki Ishida, Satoshi Tamura, Ryosuke Takano, Shinya Tani, Satoshi Osawa, Jun Nishihira, Hiroyuki Hanai; Highly bioavailable curcumin derivative ameliorates Crohn’s disease symptoms: A randomized, double-blind, multicenter study (2020) 14(12): 1693-1701; https://doi.org/10.1093/ecco-jcc/jjaa097"" is available online at: https://academic.oup.com/ecco-jcc/issue/14/12. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background & Aims: The new curcumin derivative Theracurmin? has a 27-fold higher absorption rate than natural curcumin powder. Theracurmin? is an inhibitor of nuclear factor-κB, which mediates the expression of inflammatory cytokines. The effect of Theracurmin? on inflammatory bowel disease in humans has not been explored; therefore, we investigated the efficacy and safety of Theracurmin? in patients with Crohn’s disease.
Methods: In this randomized, double-blinded study performed at 5 independent medical centers in Japan, Theracurmin? (360 mg/day, n=20) or placebo (n=10) was administered to patients with active mild-to-moderate Crohn’s disease for 12 weeks. The agent’s efficacy was assessed by evaluating clinical and endoscopic remission, healing of anal lesions, and blood levels of inflammatory markers.
Results: In the Theracurmin? group, a significant reduction in clinical disease activity was observed in week 12 relative to that in week 0 (P=0.005). On intention-to-treat analysis, clinical remission rate were 35%, 40%, and 40% at weeks 4, 8, and 12, respectively, which were significantly higher than those in the placebo group (all 0%; P=0.033, P=0.020, and P=0.020, respectively). Furthermore, reduction in endoscopic Crohn’s disease severity (P=0.032) was observed at week 12 in the Theracurmin? group. The endoscopic remission rates were 15% and 0% in the Theracurmin? and placebo groups, respectively. Significant healing of anal lesions (P=0.017) was observed at week 8 in the Theracurmin? group. No serious adverse events were observed in either group throughout the study.
Conclusions: Theracurmin? shows significant clinical and endoscopic efficacy together with afavorable safety profile in patients with active mild-to-moderate Crohn’s disease. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1873-9946 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1876-4479 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32412598 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1093/ecco-jcc/jjaa097 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
JCC-14-1693.pdf (1.2 MB)
